Alnylam Pharmaceuticals
ALNY
#1122
Rank
S$25.41 B
Marketcap
S$189.72
Share price
-0.51%
Change (1 day)
-68.47%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): S$25.35

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is S$25.56. In 2025 the company made an earnings per share (EPS) of S$2.27.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$25.351016.51%
2025S$2.27
2023S-$4.55-62%
2022S-$11.9829.03%
2021S-$9.29-3.36%
2020S-$9.61-8.48%
2019S-$10.507.67%
2018S-$9.7539.74%
2017S-$6.9812.94%
2016S-$6.1838.84%
2015S-$4.45-32.88%
2014S-$6.63259.44%
2013S-$1.84-31.25%
2012S-$2.68

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
S$6.77-73.50%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$2.55-90.00%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
S$60.61 137.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
S-$3.39-113.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
S-$0.94-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
S-$0.25-100.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$0.58-97.73%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
S-$4.30-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA